Clinical efficacy and safety analysis of M-TACE in the treatment of unresectable large hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-5782.2025.04.009

Abstract

Abstract:

Objective

The aim of this study was to evaluate the clinical efficacy and safety of multimodal-transcatheter arterial chemoembolization (M-TACE) in unresectable large hepatocellular carcinoma (HCC).

Methods

Seventeen patients with unresectable large hepatocellular carcinoma (HCC) treated with M-TACE at the interventional radiology department of Guangdong Provincial People's Hospital between March 2022 and May 2024 were retrospectively analysed. The number of treatments, tumour response at one-month follow-up, and adverse events of M-TACE were recorded.The observational indexes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

Results

The number of M-TACE treatments ranged from 1 to 14, with a median number of 6. After one month of follow-up, 13 (76.5%) patients were rated as PR, 2 (11.8%) were rated as SD, 2 (11.8%) were rated as PD, and no patient achieved CR. The ORR was 76.5% and the DCR was 88.2%. Median OS was 28 months and median PFS was 7 months. Mild complications included fever in 8 cases (47.1%), abdominal pain in 11 cases (64.7%), abdominal distension in 4 cases (23.5%), vomiting in 5 cases (29.4%), diarrhoea in 2 cases (11.8%), haemorrhage in 1 case (5.9%), infection in 4 cases (23.5%), and 2 cases of serious complications were observed as liver abscesses (11.8%).

Conclusion

For patients with unresectable large hepatocellular carcinoma, M-TACE demonstrates promising therapeutic efficacy and warrants further investigation.

Key words: three-stage mixed chemoembolic, transcatheter arterial chemoembolization, hepatocellular carcinoma, drug-eluting bead transcatheter arterial chemoembolization, interventional radiology

Suyi Ye, Ruohan Zhang, Yi Deng, Xiaoming Chen, Jing Zhang, Jing Li, Rongde Xu, Wei Cui. Clinical efficacy and safety analysis of M-TACE in the treatment of unresectable large hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2025, 13(04): 330-337.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2025.04.009

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2025/V13/I04/330

Figures/Tables 5

指标	患者（n=17）
年龄（岁， $x ¯$ ±s）	54.5±14.4
性别 [例（%）]
男性	13（76.5）
女性	4（23.5）
ECOG评分[例（%）]
0分	12（70.6）
1分	5（29.4）
乙肝病史[例（%）]
是	14（82.4）
否	3（17.6）
肝硬化[例（%）]
是	4（23.5）
否	13（76.5）
腹水[例（%）]
是	2（11.8）
否	15（88.2）
BCLC分期[例（%）]
A	6（35.3）
B	5（29.4）
C	6（35.3）
术中碘油用量 [例（%）]
<10 mL	4（23.5）
≥10mL	13（76.5）
肿瘤最大直径[例（%）]
5~10 cm	8（47.1）
>10 cm	9（52.9）
病灶数目 [例（%）]
<2个	7（41.2）
≥2个	10（58.8）
AFP [例（%）]
<200 ng/mL	8（47.1）
≥200 ng/mL	9（52.9）
门脉癌栓形成[例（%）]
是	3（17.6）
否	14（82.4）
远处转移[例（%）]
是	3（17.6）
否	14（82.4）

指标	患者（n=17）
年龄（岁， $x ¯$ ±s）	54.5±14.4
性别 [例（%）]
男性	13（76.5）
女性	4（23.5）
ECOG评分[例（%）]
0分	12（70.6）
1分	5（29.4）
乙肝病史[例（%）]
是	14（82.4）
否	3（17.6）
肝硬化[例（%）]
是	4（23.5）
否	13（76.5）
腹水[例（%）]
是	2（11.8）
否	15（88.2）
BCLC分期[例（%）]
A	6（35.3）
B	5（29.4）
C	6（35.3）
术中碘油用量 [例（%）]
<10 mL	4（23.5）
≥10mL	13（76.5）
肿瘤最大直径[例（%）]
5~10 cm	8（47.1）
>10 cm	9（52.9）
病灶数目 [例（%）]
<2个	7（41.2）
≥2个	10（58.8）
AFP [例（%）]
<200 ng/mL	8（47.1）
≥200 ng/mL	9（52.9）
门脉癌栓形成[例（%）]
是	3（17.6）
否	14（82.4）
远处转移[例（%）]
是	3（17.6）
否	14（82.4）

References 20

[1]	Eggert T, Greten T F. Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma[J]. Digestion, 2017, 96(1): 1-4.
[2]	Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review[J]. Liver Cancer, 2012, 1(3-4): 144-158.
[3]	Duan X, Li H, Kuang D, et al. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase Ⅲ trial[J]. Signal Transduct Target Ther, 2024, 9(1): 304.
[4]	Zhang W, Chen L, Cao Y, et al. Efficacy of drug-eluting beads transarterial chemoembolization plus apatinib compared with conventional transarterial chemoembolization plus apatinib in the treatment of unresectable hepatocellular carcinoma[J]. Cancer Manag Res, 2021, 13: 5391-5402.
[5]	Yang Y, Du N, Ma J, et al. Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma[J]. J Hepatocell Carcinoma, 2023, 10: 1897-1910.
[6]	Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1. 1 and mRECIST (modified RECIST): JIVROSG-0602[J]. Ups J Med Sci, 2013, 118(1): 16-22.
[7]	Dariushnia S R, Redstone E A, Heran M K S, et al. Society of interventional radiology quality improvement standards for percutaneous transcatheter embolization[J]. J Vasc Interv Radiol, 2021, 32(3): 476. e1-476. e33.
[8]	Lu W, Jin X L, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6): 433-438.
[9]	Qin S, Bai Y, Lim H Y, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
[10]	Park J W, Kim Y J, Kim D Y, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase Ⅲ STAH trial[J]. J Hepatol, 2019, 70(4): 684-691.
[11]	Chang B, Zhou C, Liu C, et al. Clinical outcomes of modified transarterial chemoembolization vs. drug-eluting bead transarterial chemoembolization as initial treatment for single hepatocellular carcinoma: a propensity score matching analysis[J]. Ann Med, 2024, 56(1): 2423787.
[12]	Lu E, Shao G, Ma J, et al. Optimized loading of Idarubicin in CalliSpheres(®) drug-eluting beads and characterization of release profiles and morphological properties[J]. Pharmaceutics, 2021, 13(6): 799.
[13]	Martin R C G, 2nd, Simo K A, Hansen P, et al. Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin[J]. Ann Surg Oncol, 2022, 29(9): 5462-5473.
[14]	Cheng A L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873.
[15]	Kim G H, Kim J H, Shim J H, et al. Chemoembolization for single large hepatocellular carcinoma with preserved liver function: analysis of factors predicting clinical outcomes in a 302 patient cohort[J]. Life (Basel), 2021, 11(8): 840.
[16]	Chen M S, Li J Q, Zhang Y Q, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma[J]. World J Gastroenterol, 2002, 8(1): 74-78.
[17]	Hai L, Liu S, Ma L, et al. Comparative study of the short-term efficacy and safety between DEB-TACE and C-TACE in the treatment of unresectable hepatocellular carcinoma, a retrospective study[J]. Technol Cancer Res Treat, 2024, 23: 15330338241250315.
[18]	Wu G C, Chan E D, Chou Y C, et al. Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors[J]. Anticancer Drugs, 2014, 25(8): 976-981.
[19]	Grinsell D, Rajkomar A K S, Rozen W M, et al. Refining our knowledge of macrovascular arteriovenous shunts (MAS): anatomical and pathological studies[J]. J Plast Reconstr Aesthet Surg, 2020, 73(8): 1490-1498.
[20]	Arslan M, Degirmencioglu S. Liver abscesses after transcatheter arterial embolization[J]. J Int Med Res, 2019, 47(3): 1124-1130.

Please choose a citation manager

Content to export